Omar Chamdine1, Alberto Broniscer1,2, Shengjie Wu3, Amar Gajjar1, Ibrahim Qaddoumi1. 1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, Tennessee. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
BACKGROUND: Patients with low-grade gliomas (LGG), which are the most common childhood brain tumors, have excellent long-term survival. Dissemination of LGG is rare. Robust data on the incidence, presentation, patterns of dissemination, disease behavior, outcome, and best-management approaches do not exist. We describe 20 years of follow-up of children with metastatic LGG. PROCEDURE: Data collected during the period 1990-2010 were retrospectively reviewed for the following inclusion criteria: diagnosis of metastatic LGG, age younger than 21 years at initial diagnosis, and magnetic resonance imaging of the brain and/or spine at diagnosis and/or follow-up. Patient demographics, pathology, treatment modalities, and outcome were reviewed. RESULTS: Of 599 patients with LGG, 38 (6%) had metastatic disease at either diagnosis or follow-up. Most tumors (87%) were located in the brain, and half of the patients had metastatic disease at presentation. The most common diagnosis was pilocytic astrocytoma (55%). Chemotherapy was the most common initial treatment modality. Median survival of the group was 6.2 years (range, 0.1-16.9 years). Fifteen (40%) patients died at a median of 6 years from diagnosis (range, 0.8-15 years). Overall survival at 5, 10, and 15 years was 80.7 ± 6.6%, 63.0 ± 10.2%, and 50.9 ± 16.0%, respectively. CONCLUSION: This study describes the longest follow-up of children with metastatic LGG. LGG is underestimated and entails major morbidity and mortality. Prospective studies are needed to learn the true incidence, study the biology, and determine the best approaches to diagnosis, treatment, and follow-up.
BACKGROUND:Patients with low-grade gliomas (LGG), which are the most common childhood brain tumors, have excellent long-term survival. Dissemination of LGG is rare. Robust data on the incidence, presentation, patterns of dissemination, disease behavior, outcome, and best-management approaches do not exist. We describe 20 years of follow-up of children with metastatic LGG. PROCEDURE: Data collected during the period 1990-2010 were retrospectively reviewed for the following inclusion criteria: diagnosis of metastatic LGG, age younger than 21 years at initial diagnosis, and magnetic resonance imaging of the brain and/or spine at diagnosis and/or follow-up. Patient demographics, pathology, treatment modalities, and outcome were reviewed. RESULTS: Of 599 patients with LGG, 38 (6%) had metastatic disease at either diagnosis or follow-up. Most tumors (87%) were located in the brain, and half of the patients had metastatic disease at presentation. The most common diagnosis was pilocytic astrocytoma (55%). Chemotherapy was the most common initial treatment modality. Median survival of the group was 6.2 years (range, 0.1-16.9 years). Fifteen (40%) patients died at a median of 6 years from diagnosis (range, 0.8-15 years). Overall survival at 5, 10, and 15 years was 80.7 ± 6.6%, 63.0 ± 10.2%, and 50.9 ± 16.0%, respectively. CONCLUSION: This study describes the longest follow-up of children with metastatic LGG. LGG is underestimated and entails major morbidity and mortality. Prospective studies are needed to learn the true incidence, study the biology, and determine the best approaches to diagnosis, treatment, and follow-up.
Authors: Tore Stokland; Jo-Fen Liu; James W Ironside; David W Ellison; Roger Taylor; Kathryn J Robinson; Susan V Picton; David A Walker Journal: Neuro Oncol Date: 2010-09-22 Impact factor: 12.300
Authors: Taylor J Abel; Abhineet Chowdhary; Mahesh Thapa; Joe C Rutledge; J Russell Geyer; Jeffrey Ojemann; Anthony M Avellino Journal: J Neurosurg Date: 2006-12 Impact factor: 5.115
Authors: Stephan von Hornstein; Rolf-D Kortmann; Torsten Pietsch; Angela Emser; Monika Warmuth-Metz; Niels Soerensen; Ronald Straeter; Norbert Graf; Barbara Thieme; Astrid K Gnekow Journal: Pediatr Blood Cancer Date: 2011-02-11 Impact factor: 3.167
Authors: Barbara J Fisher; Elitza Naumova; Christopher C Leighton; George N Naumov; Nancy Kerklviet; David Fortin; David R Macdonald; J Gregory Cairncross; Glenn S Bauman; Larry Stitt Journal: Int J Radiat Oncol Biol Phys Date: 2002-03-15 Impact factor: 7.038
Authors: R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett Journal: J Neurosurg Date: 1997-05 Impact factor: 5.115
Authors: Pratiti Bandopadhayay; Guillaume Bergthold; Wendy B London; Liliana C Goumnerova; Andres Morales La Madrid; Karen J Marcus; Dongjing Guo; Nicole J Ullrich; Nathan J Robison; Susan N Chi; Rameen Beroukhim; Mark W Kieran; Peter E Manley Journal: Pediatr Blood Cancer Date: 2014-01-30 Impact factor: 3.167
Authors: Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Derek S Tsang; Erin S Murphy; Sharon E Ezell; John T Lucas; Christopher Tinkle; Thomas E Merchant Journal: J Neurooncol Date: 2017-06-17 Impact factor: 4.130
Authors: Margot A Lazow; Lindsey Hoffman; Austin Schafer; Diana S Osorio; Daniel R Boué; Sarah Rush; Erin Wright; Adam Lane; Mariko D DeWire-Schottmiller; Teresa Smolarek; Jared Sipple; Heather Taggert; Jaime Reuss; Ralph Salloum; Trent R Hummel; Peter de Blank; Natasha Pillay-Smiley; Mary E Sutton; Anthony Asher; Charles B Stevenson; Rachid Drissi; Jonathan L Finlay; Maryam Fouladi; Christine Fuller Journal: Acta Neuropathol Commun Date: 2020-11-05 Impact factor: 7.801